

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**FOSUN PHARMA**

**复星医药**

**上海復星醫藥（集團）股份有限公司**

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02196)**

**TRADING HALT**

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**”) refers to the announcement of its subsidiary Shanghai Henlius Biotech, Inc. (“**Henlius**”) dated 23 May 2024 in connection with the trading halt of Henlius’s H shares.

Trading in the H shares of the Company on The Stock Exchange of Hong Kong Limited has been halted with effect from 9:00 a.m. on 23 May 2024 pending the publication by the Company of an announcement in relation to the above.

By order of the Board

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

**Wu Yifang**

*Chairman*

Shanghai, the PRC

23 May 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.*

\* *For identification purposes only*